Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract Cancer

Daniel H. Ahn, MD
Published: Thursday, Jun 16, 2016


Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer (BTC) to reveal the association between tumor somatic variants and chemotherapy resistance.

A rise in the incidence of BTC, which affects both the liver and the bile duct in patients, has been reported in recent years, Ahn explains. Chemotherapy remains the first- and second-line treatment option for refractory patients.

A multicenter, retrospective study examined patients who underwent next-geneyearation sequencing and received treatment with gemcitabine and cisplatin. This was done in order to determine if there was an association with chemotherapy resistance. Some mutations detected were found to be targetable and actionable, including TP53, CKDN2A, and ARID1A. Therefore, clinical trials designed to target these mutations with novel agents should be done, Ahn adds.

 

Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer (BTC) to reveal the association between tumor somatic variants and chemotherapy resistance.

A rise in the incidence of BTC, which affects both the liver and the bile duct in patients, has been reported in recent years, Ahn explains. Chemotherapy remains the first- and second-line treatment option for refractory patients.

A multicenter, retrospective study examined patients who underwent next-geneyearation sequencing and received treatment with gemcitabine and cisplatin. This was done in order to determine if there was an association with chemotherapy resistance. Some mutations detected were found to be targetable and actionable, including TP53, CKDN2A, and ARID1A. Therefore, clinical trials designed to target these mutations with novel agents should be done, Ahn adds.

 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x